Bruker makes high-end scientific instruments—mass spectrometers, microscopes, and X-ray tools—used in labs for drug discovery, materials research, and diagnostics. Think of it as the precision toolbox for scientists who need to see and measure things at the mo
Revenue is $3.44B, with a gross margin of 45.91%. But the latest quarter (June 2026) shows an operating loss of -$0.07B and a net loss of -$0.05B, dragging the trailing net margin to -0.25%. Money comes from selling instruments and consumables, but profitabili
Bruker's edge comes from deep technical expertise and patented designs in niche fields like MALDI Biotyper and AFM, which competitors like Thermo Fisher and Danaher can't easily copy. However, the recent losses suggest the moat is eroding, as pricing pressure
Sell (sector percentile 6) — value C, growth D-, profitability C+, momentum B+, revisions D-. Updated daily, sector-relative, identical for every user.
Key events, in time order
Earnings beat expectations, but valuation worries drove shares down 17%
BNY Mellon reduced its Bruker position by 6.6% in Q1 2026, adding to recent institutional moves.
None yet
None yet
Bruker is identified as one of the strongest moving stocks above $1B market cap, indicating positive momentum within its industry group.
Main discussion
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
